Dmitry Gabrilovich

Dmitry Gabrilovich, MD, Ph.D., is a Chief Scientist, Cancer Immunology, AstraZeneca. Dr. Gabrilovich studied dendritic cell (DC) biology under Dr. Stella C. Knight at the Imperial College of London in the UK and then trained in cancer research at U.T. Southwestern Medical School and Vanderbilt University in the laboratory of Dr. D. Carbone.

In mid 1990s his group demonstrated, that DCs in cancer were functionally impaired. They have described the first tumor-derived factor directly implicated in DC defects in cancer and suggested that myeloid progenitor cells were the main targets for this negative effect. His group implicated lipid accumulation as one of the mechanisms negatively regulating function of DCs in cancer. Dr. Gabrilovich, together with Dr. Bronte had discovered cells that now called myeloid-derived suppressor cells (MDSC). His group characterized these cells, number of molecular mechanisms regulating expansion and function of these cells. His group provided first evidence that MDSC can be therapeutically targeted in patients. Dr. Gabrilovich was involved in number of clinical trials testing the effect of cancer vaccines and small molecules and antibodies that target myeloid cells.

Dr. Gabrilovich was Robert Rothman Endowed Chair in Cancer Research and Head, Section of Dendritic Cell Biology at H. Lee Moffitt Cancer Center and then Christopher M. Davis Professor in Cancer Research at the Wistar Institute in Philadelphia and Wistar Professor at the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania. Dr. Gabrilovich is American Cancer Society Research Professor and during last 6 years is listed as one of the most highly cited researchers in the field of Immunology by Clarivate Analytics.